Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Common Equity (2022 - 2025)

Cannabis Bioscience International Holdings' Common Equity history spans 4 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Common Equity fell 20.12% year-over-year to -$1.4 million; the TTM value through Nov 2025 reached -$1.4 million, down 20.12%, while the annual FY2025 figure was -$1.2 million, 7.84% down from the prior year.
  • Common Equity for Q4 2025 was -$1.4 million at Cannabis Bioscience International Holdings, down from -$1.2 million in the prior quarter.
  • Across five years, Common Equity topped out at -$405301.0 in Q4 2022 and bottomed at -$1.4 million in Q4 2025.
  • The 4-year median for Common Equity is -$1.1 million (2024), against an average of -$944755.2.
  • The largest annual shift saw Common Equity crashed 107.72% in 2023 before it fell 7.84% in 2025.
  • A 4-year view of Common Equity shows it stood at -$405301.0 in 2022, then plummeted by 107.72% to -$841886.0 in 2023, then plummeted by 34.8% to -$1.1 million in 2024, then decreased by 20.12% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CBIH's Common Equity are -$1.4 million (Q4 2025), -$1.2 million (Q3 2025), and -$1.2 million (Q2 2025).